Build Your Next Discovery on Real-world Molecular Depth
Translational360™ connects advanced molecular testing with real-world context to drive precision oncology research forward.
Molecular Intelligence Meets Real-World Context
Translational360™ integrates EMR, claims, and SDoH with high-resolution molecular datasets from industry-leading partners. This dataset enables the creation of real-world translational cohorts - aligned to clinical trial endpoints and molecular stratification needs.
Key Benefits of Translational360™
.svg)
Comprehensive
Access the whole exome, transcriptome, and circulating tumor data - matched to curated clincal records and outcomes.
.svg)
Flexible
Build cohorts by biomarker, tumor type, therapy exposure, or resistance patterns across solid and hematologic cancers.
.svg)
Real-World Ready
Designed to reflect the complexity of real-world patients, including comorbidities, prior treatments, and equity considerations.
.svg)
Trial Accelerator
Aligns with pre-clinical and translational research priorities to drive discovery and validation.
Core Capabilities of Translational360™
Whole Exome + Transcriptome Data
Deeper Genomics from the Tumor Core
- DNA + RNA data for drug response and resistance
- Matched to full clinical & therapy history
- Ideal for solid tumor cohort building and drug discovery
Liquid Biopsy Genomics
Real-Time, Non-Invasive Molecular Data
- ctDNA profiling from blood samples
- Detect early resistance and recurrence markers
- Supports longitudinal monitoring
- Expands Cohort reach beyond biopsy-accessible tumors
Heme-Malignancy Genomics
Pan-Heme Coverage, 500+ Biomarkers
- Covers 30+ hematologic diseases
- FISH, cytogenetics, NGS, flow cytometry
- Companion diagnostic support for targeted therapies
- Includes mutation panels for AML, MDS, MM, CLL, and more...
Linked Real-World Clinical Context
Data That Mirrors Patient Reality
- 200+ EMR variables including ECOG, labs, and therapies
- SDoH and payer data for health equity insights
- Integrated line-of-therapy and comorbidity models
- Custom curation available to match trial designs
Value Add of the Linked Data Product
Enhanced Patient Journey Tracking
An NPM1+ and FLT3+ AML Patient's Journey
Background
The graph on the right shows data from a single AML NPM1+ at diagnosis, and FLT3+ at-relapse, Patient. This patient (72yo, F) was diagnosed with therapy-related AML in May 2020 and treated with HMA + Ven. Remission mid-2021, relapse Oct 2022. Ven + Gilteritinib through early- to mid-2023
Methods
Multi-modal Transcriptome360™ Structured EMR and Open Claims (with >95% overlap) and NeoGenomics NGS and Karyotype data was used
Insights Generated
Biomarker Report: NeoGenomics report at diagnosis (May 2020) with Normal Karyotype 46,XX [20]. NPM1+ at diagnosis. Limited NPM1+ targeted therapies at diagnosis. TET2+ and ASXL1- are associated with increased HMA response. FLT3+ at relapse (Oct. 2022). Patient responding well with respect to AML disease through end of 2023
Clinical: EMR contributes ECOG directly (0 at Dx, 1 2021+), BMI (30+), and lab results. Claims + EMR adds many co-morbidities, transplant (early 2023), and many transfusions post relapse.
.png?width=1080&height=1080&name=Translational360TM%20(3).png)